View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 24, 2018

AOBiome starts Phase II trial of AOB for episodic migraine

AOBiome Therapeutics has commenced a Phase II clinical study evaluating the safety, tolerability, and efficacy of its Ammonia Oxidizing Bacteria (AOB) product candidate for the treatment of episodic migraine.

AOBiome Therapeutics has commenced a Phase II clinical study evaluating the safety, tolerability, and efficacy of its Ammonia Oxidizing Bacteria (AOB) product candidate for the treatment of episodic migraine.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The randomised, double-blind trial aims to enrol 303 patients with episodic migraine.

As part of the trial, AOB will be delivered as an intranasal spray to patients, who will be randomised 1:1:1 in three arms including lower dose AOB, higher dose AOB, and vehicle.

The trial’s primary endpoint is safety, while the secondary endpoints include the measurement of mean change and reductions in migraine days and attacks.

"Initiation of our migraine study extends our AOB pipeline to a broad neurology indication for the first time."

The company’s AOB product candidate is a single strain of beneficial AOB, Nitrosomonaseutropha. This converts naturally occurring ammonia to nitric oxide, a signalling molecule that can regulate inflammation and vasodilation, and to nitrite, altered levels of which are linked to migraines.

AOBiome Therapeutics president and CEO Todd Krueger said: “Initiation of our migraine study extends our AOB pipeline to a broad neurology indication for the first time.

“The trial also further builds on our capabilities in intranasal delivery, which has recently shown promising safety data in treating individuals with seasonal allergic rhinitis.”

California Medical Clinic for Headache director David Kudrow said that migraine is estimated to be the third most common disease in the world and is claimed to be one of the top six most disabling illnesses.

Currently, limited options are available to treat migraine, with over 50% patients starting to take preventive medications stop taking them within six months either because of their ineffectiveness or non-tolerance.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena